RETRACTABLE TECHNOLOGIES INC
Close on Oct 19, 2026
- Market cap
- $17.30M
- P/E (TTM)
- –
- Dividend yield
- –
About Retractable Technologies
Surgical & Medical Instruments & Apparatus, SIC 3841
Retractable Technologies, Inc. designs, manufactures, and markets safety medical devices for the healthcare industry, with a primary focus on injection equipment. Its principal offerings include retractable syringes and needles sold under brand names such as VanishPoint, Patient Safe, and EasyPoint, which feature safety mechanisms designed to prevent needlestick injuries, inhibit reuse, and reduce medication waste. The company markets its products primarily to healthcare providers through group purchasing organizations, specialty distributors, and a direct marketing network.
The company operates manufacturing facilities, warehousing, and administrative offices in Little Elm, Texas, while also utilizing third-party contract manufacturers in China. Most of its sales are distributed within the United States, though it also serves international healthcare markets through global distributors. Retractable Technologies is based in Texas, where it maintains its corporate headquarters alongside its primary domestic manufacturing operations.
Summary of the business section of Retractable Technologies's latest annual report, written by StockData.
Company profile
Company
- Legal name
- RETRACTABLE TECHNOLOGIES INC
- Founded
- 1994
- Headquarters
- Little Elm, TX
- Address
- 511 Lobo Lane 75068-0009
- Phone
- (972) 294-1010
- Website
- retractable.com
- Employees
- 201, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Texas
- Fiscal year ends
- December 31
- Auditor
- Baker Tilly US, LLP, Dallas, TX
Stock & identifiers
- Ticker
- RVP
- Exchange
- NYSE
- IPO date
- May 4, 2001
- Shares outstanding
- 30M, Aug 1, 2026
- Public float
- $8.10M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 946563
- CUSIP
- 76129W105
- ISIN
- US76129W1053
- EIN
- 75-2599762
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Thomas J. Shaw | PRESIDENT AND CEO, Director | 16,662,822 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $1.22M | $1.22M | $304.33K | $7 | $115 |
| FY2024 | $1.19M | $1.19M | $279.35K | $7 | $107 |
| FY2023 | $1.15M | $1.15M | $280.46K | $10 | $99 |
| FY2022 | $1.08M | $8.58M | $276.44K | $15 | $97 |
| FY2021 | $11.52M | $4.02M | $1.27M | $65 | $121 |
| FY2020 | $516.72K | $516.72K | $277.54K | $716 | $124 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of March 9, 2026, we had 201 employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jun 6, 2025 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Jul 6, 2016 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Nov 14, 2011 | Late filing | Notification of late filing |
| May 2, 2001 | Listing | Registration of securities on an exchange (Form 8-A) |